Company intelligence / Profile preview

Inprint

Ownership: Private
Development stage: Commercial

Overview

Imprint aims to decode the body's immune memory using advanced sequencing and computational methods. The goal is to uncover causal links between infections and chronic/autoimmune disease by mapping "trigger-target" relationships at scale. Their technology will be made open access for broad research use. No clinical results as they are not developing therapeutics directly yet

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Industry: Academic Hospital/University/Research

Partnerships

Eric & Wendy Schmidt PhilanthropiesConvergent ResearchNew York City Economic Development CorporationPeter ReinhardtKenneth C. Griffin from Griffin Catalyst

Beyond the preview

Go deeper on Inprint.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inprint.

Explore the full profile